These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 1913697

  • 1. The treatment of orthostatic hypotension with dihydroxyphenylserine.
    Freeman R, Landsberg L.
    Clin Neuropharmacol; 1991 Aug; 14(4):296-304. PubMed ID: 1913697
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Droxidopa in neurogenic orthostatic hypotension.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA.
    Expert Rev Cardiovasc Ther; 2015 Aug; 13(8):875-91. PubMed ID: 26092297
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 6. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O.
    Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
    [Abstract] [Full Text] [Related]

  • 7. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
    Mathias CJ.
    Clin Auton Res; 2008 Mar; 18 Suppl 1():25-9. PubMed ID: 18368304
    [Abstract] [Full Text] [Related]

  • 8. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 9. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 22; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 10. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 11. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
    Gupta F, Kremens D, Vernino S, Karabin B.
    Clin Auton Res; 2017 Jul 12; 27(Suppl 1):9-11. PubMed ID: 28699048
    [No Abstract] [Full Text] [Related]

  • 12. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
    Ho AH, Kinter CW, Wight J, Neelam AR, Krakow D.
    J Med Case Rep; 2020 Jun 20; 14(1):73. PubMed ID: 32560740
    [Abstract] [Full Text] [Related]

  • 13. New developments in the management of neurogenic orthostatic hypotension.
    Biaggioni I.
    Curr Cardiol Rep; 2014 Nov 20; 16(11):542. PubMed ID: 25303896
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.
    J Am Soc Hypertens; 2016 Oct 20; 10(10):755-762. PubMed ID: 27614923
    [Abstract] [Full Text] [Related]

  • 15. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Claassen D, Lew M.
    Clin Auton Res; 2017 Jul 20; 27(Suppl 1):13-14. PubMed ID: 28631224
    [No Abstract] [Full Text] [Related]

  • 16. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
    Lamotte G, Holmes C, Sullivan P, Goldstein DS.
    Clin Auton Res; 2019 Feb 20; 29(1):113-117. PubMed ID: 30229336
    [Abstract] [Full Text] [Related]

  • 17. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
    Carvalho MJ, van den Meiracker AH, Boomsma F, Man in 't Veld AJ, Freitas J, Costa O, de Freitas AF.
    J Auton Nerv Syst; 1997 Jan 12; 62(1-2):63-71. PubMed ID: 9021651
    [Abstract] [Full Text] [Related]

  • 18. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.
    Suzuki T, Higa S, Sakoda S, Hayashi A, Yamamura Y, Takaba Y, Nakajima A.
    Neurology; 1981 Oct 12; 31(10):1323-6. PubMed ID: 6287350
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
    White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA.
    Am J Cardiol; 2017 Apr 01; 119(7):1111-1115. PubMed ID: 28159196
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the norepinephrine transporter to treat neurogenic orthostatic hypotension: is this the end of the story?
    Lamotte G, Millar Vernetti P.
    Clin Auton Res; 2021 Dec 01; 31(6):645-647. PubMed ID: 34757507
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.